Literature DB >> 19628219

Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Emily A Kendall1, Elsa González, Iván Espinoza, Martín Tipismana, Kristien Verdonck, Daniel Clark, Sten H Vermund, Eduardo Gotuzzo.   

Abstract

OBJECTIVE: Because human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) may occur in some children infected with HTLV-1, we sought to determine the prevalence of neurologic abnormalities and any associations of neurologic abnormalities with infective dermatitis in these children. STUDY
DESIGN: We enrolled 58 children infected with HTLV-1 and 42 uninfected children (ages 3 to 17) of mothers infected with HTLV-1 in a family study in Lima, Peru. We obtained medical and developmental histories, surveyed current neurologic symptoms, and conducted a standardized neurologic examination without prior knowledge of HTLV-1 status.
RESULTS: HTLV-1 infection was associated with reported symptoms of lower extremity weakness/fatigue (odds ratio [OR], 6.1; confidence interval [CI], 0.7 to 281), lumbar pain (OR, 1.7; 95% CI, 0.4 to 8), and paresthesia/dysesthesia (OR, 2.6; CI, 0.6 to 15.8). HTLV-1 infection was associated with lower-extremity hyperreflexia (OR, 3.1; CI, 0.8 to 14.2), ankle clonus (OR, 5.0; CI, 1.0 to 48.3), and extensor plantar reflex (OR undefined; P = .2). Among children infected with HTLV-1, a history of infective dermatitis was associated with weakness (OR, 2.7; CI, 0.3 to 33), lumbar pain (OR, 1.3; CI, 0.2 to 8), paresthesia/dysesthesia (OR, 2.9; CI, 0.5 to 20), and urinary disturbances (OR, 5.7; CI, 0.5 to 290).
CONCLUSIONS: Abnormal neurologic findings were common in Peruvian children infected with HTLV-1, and several findings were co-prevalent with infective dermatitis. Pediatricians should monitor children infected with HTLV-1 for neurologic abnormalities.

Entities:  

Mesh:

Year:  2009        PMID: 19628219      PMCID: PMC2764792          DOI: 10.1016/j.jpeds.2009.05.027

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  56 in total

1.  Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM).

Authors:  Carlos M De Castro-Costa; Abelardo Q C Araújo; Márcio M Barreto; Osvaldo M Takayanagui; Marzia P Sohler; Eduardo L M da Silva; Sônia M B de Paula; Ricardo Ishak; João G R Ribas; Luis C Rovirosa; Herwig Carton; Eduardo Gotuzzo; William W Hall; Silvia Montano; Edward L Murphy; Joel Oger; Carlos Remondegui; Graham P Taylor
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

2.  Infective dermatitis: a pabulum for human T-lymphotrophic virus type I leukemogenesis?

Authors:  E Tschachler; G Franchini
Journal:  Arch Dermatol       Date:  1998-04

3.  High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in peru.

Authors:  Jorge O Alarcón; Heidi B Friedman; Silvia M Montano; Joseph R Zunt; King K Holmes; Gerald V Quinnan
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

4.  Infective dermatitis associated with the human T cell lymphotropic virus type I in Salvador, Bahia, Brazil.

Authors:  Maria de Fatima S P de Oliveira; Carlos Brites; Neide Ferraz; Paula Magalhaes; Fabricio Almeida; Achilea L Bittencourt
Journal:  Clin Infect Dis       Date:  2005-04-27       Impact factor: 9.079

5.  Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding.

Authors:  S Z Wiktor; E J Pate; P S Rosenberg; M Barnett; P Palmer; D Medeiros; E M Maloney; W A Blattner
Journal:  J Hum Virol       Date:  1997 Nov-Dec

6.  Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study.

Authors:  Stéphane Olindo; Philippe Cabre; Agnes Lézin; Harold Merle; Martine Saint-Vil; Aissatou Signate; Mickael Bonnan; Aurelie Chalon; Lionel Magnani; Raymond Cesaire; Didier Smadja
Journal:  Arch Neurol       Date:  2006-11

7.  Infective dermatitis and human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in childhood and adolescence.

Authors:  Janeusa Rita L Primo; Carlos Brites; Maria de Fátima S P de Oliveira; Otávio Moreno-Carvalho; Marcos Machado; Achiléa L Bittencourt
Journal:  Clin Infect Dis       Date:  2005-07-08       Impact factor: 9.079

8.  Histopathological and immunohistochemical studies of infective dermatitis associated with HTLV-I.

Authors:  Achiléa L Bittencourt; Maria de Fátima Oliveira; Carlos Brites; Johan Van Weyenbergh; Maria das Graças da Silva Vieira; Iguaracyra Araújo
Journal:  Eur J Dermatol       Date:  2005 Jan-Feb       Impact factor: 3.328

9.  [Tropical spastic paraparesis and HTLV-I associated myelopathy in infancy. A case report and review of the literature].

Authors:  S Quintas; T Moreno; N Lobo-Antunes; A Levy-Gomes
Journal:  Rev Neurol       Date:  2004 Dec 16-31       Impact factor: 0.870

Review 10.  Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL).

Authors:  Masao Matsuoka
Journal:  Retrovirology       Date:  2005-04-26       Impact factor: 4.602

View more
  10 in total

Review 1.  [Vertical transmission of HTLV-1 in Peru].

Authors:  Jorge Alarcón Villaverde; Franco Romaní Romaní; Silvia Montano Torres; Joseph R Zunt
Journal:  Rev Peru Med Exp Salud Publica       Date:  2011-03

2.  Unusual segmental narrowing of spinal cord responsible for child paraparesis.

Authors:  Eleonora Briatore; Andrea Boghi; Barbara Podestà; Luigi Gozzoli; Stefano Calzolari
Journal:  Neurol Sci       Date:  2011-02-03       Impact factor: 3.307

Review 3.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

4.  HTLV-1-associated myelopathy in a solid organ transplant recipient.

Authors:  Maria Jose Montesdeoca Andrade; Edgar Patricio Correa Diaz; Maria Eugenia Buestán
Journal:  BMJ Case Rep       Date:  2016-06-06

5.  HTLV-1-associated infective dermatitis and probable HTLV-1- associated myelopathy in an adolescent female.

Authors:  Raquel Bisacotti Steglich; Renata Elise Tonoli; Paulo Ricardo Martins Souza; Giselle Martins Pinto; Rudimar dos Santos Riesgo
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

Review 6.  Emerging and re-emerging infectious diseases in Iran.

Authors:  Najmeh Parhizgari; Mohammad Mehdi Gouya; Ehsan Mostafavi
Journal:  Iran J Microbiol       Date:  2017-06

7.  Estimation of HTLV-1 vertical transmission cases in Brazil per annum.

Authors:  Carolina Rosadas; Bassit Malik; Graham P Taylor; Marzia Puccioni-Sohler
Journal:  PLoS Negl Trop Dis       Date:  2018-11-12

Review 8.  A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan.

Authors:  Kazuo Itabashi; Tokuo Miyazawa; Akihiko Sekizawa; Akifumi Tokita; Shigeru Saito; Hiroyuki Moriuchi; Yasuhito Nerome; Kaoru Uchimaru; Toshiki Watanabe
Journal:  Front Microbiol       Date:  2020-04-09       Impact factor: 5.640

9.  Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy.

Authors:  Britta Moens; Daniele Decanine; Soraya Maria Menezes; Ricardo Khouri; Gilvanéia Silva-Santos; Giovanni Lopez; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Ramon de Almeida Kruschewsky; Bernardo Galvão-Castro; Anne-Mieke Vandamme; Johan Van Weyenbergh
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

Review 10.  Pain prevalence, characteristics and associated factors in human T-cell lymphotropic virus type 1 infected patients: a systematic review of the literature.

Authors:  Daniel Lordelo San-Martin; Dislene Nascimento Dos Santos; Abrahão Fontes Baptista
Journal:  Braz J Infect Dis       Date:  2016-10-18       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.